BioMarin impresses with Phase II dwarfism drug
This article was originally published in Scrip
Executive Summary
BioMarin Pharmaceuticals has raised expectations for its dwarfism product BMN-111 (vosoritide) on the back of strong Phase II data.
You may also be interested in...
BioMarin Eyes Late 2021 Launch As Achondroplasia Drug Succeeds In Phase III
R&D president Hank Fuchs said vosoritide can be filed based on height gains for children and safety in babies and toddlers with the most common form of dwarfism, but timing depends on meetings with regulators.
Pfizer Grows In Rare Disease With $810m Dwarfism Company Buy
Pfizer adds to its rare disease portfolio with purchase of Therachon, a Swiss company working in achondroplasia. But whether it can catch up with Biomarin’s Phase III vosoritide is still to be seen.
Therachon Moves 'Academic Prototype' Towards Clinic
Emerging Company Profile: Switzerland-based Therachon is developing therapeutics for rare genetic pediatric diseases with a lead program in achondroplasia, also known as genetic dwarfism. CEO Luca Santarelli explains the mechanism behind lead molecule TA-46 and plans moving forward.